ArticleInternational journal of biological sciences2021
The role of N-cadherin/c-Jun/NDRG1 axis in the progression of prostate cancer.
Article in International journal of biological sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- Spatial and single-cell profiling identify NDRG1⁺ macrophages as key hallmark of angiogenic remodeling and platinum resistance in HGSOC.Translational oncology · 2026Article
- Uncovering genes driving developmental stage progression in prostate cancer through spatial transcriptomics.Genes & diseases · 2026Article
- iS2C2: a cointelligent platform for mechanistic discovery of disease cellular crosstalk.Signal transduction and targeted therapy · 2026Article
- Druggable Mendelian randomization prioritizes CDH2 and supports finerenone as a candidate therapeutic strategy for diabetic retinopathy.Frontiers in pharmacology · 2026Article
- Investigation of the antitumor effects of deferasirox on prostate cancer cells: insights into proliferation, apoptosis, and invasion mechanisms.Molecular biology reports · 2025Article
- The diagnostic value of prostate health index combined with soluble e-cadherin for prostate cancer.Frontiers in endocrinology · 2025Article
- Spatial transcriptomics identifies RBM39 as a gene aiScience · 2024Article
- Differential analysis of histopathological and genetic markers of cancer aggressiveness, and survival difference in EBV-positive and EBV-negative prostate carcinoma.Scientific reports · 2024Article
- Visium spatial transcriptomics reveals intratumor heterogeneity and profiles of Gleason score progression in prostate cancer.iScience · 2023Article
- Cardiac tropoini T (TNNT2) plays a potential oncogenic role in colorectal carcinogenesis.Cancer cell international · 2023Article
- A review on the role of NDRG1 in different cancers.Molecular biology reports · 2023Review
- The Emerging Role of Cell Adhesion Molecules on Benign Prostatic Hyperplasia.International journal of molecular sciences · 2023Review
- Cell-Type-Specific Signalling Networks Impacted by Prostate Epithelial-Stromal Intercellular Communication.Cancers · 2023Article
- Article
- Construction of a risk prediction model using m6A RNA methylation regulators in prostate cancer: comprehensive bioinformatic analysis and histological validation.Cancer cell international · 2022Article
- Dissecting the effects of androgen deprivation therapy on cadherin switching in advanced prostate cancer: A molecular perspective.Oncology research · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The dysregulation of androgen receptor (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.